Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx ...
In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...
Elevance Health reported stronger-than-expected results and raised its dividend as it benefited from higher premiums, ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a ...
Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...
Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting." ...
StockNews.com cut shares of Elevance Health (NYSE:ELV – Free Report) from a buy rating to a hold rating in a research note ...
Elevance Health Inc. closed 27.50% below its 52-week high of $567.26, which the company achieved on September 3rd.
Elevance Health is happy with the performance of its commercial health insurance business, but not happy enough to take an optimistic approach to setting premiums. Elevance executives talked about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback